| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Myeloid cell factor-1 is a critical survival factor for multiple myeloma.
|
Blood
|
2002
|
2.68
|
|
2
|
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
|
Blood
|
2006
|
1.59
|
|
3
|
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
|
Leuk Lymphoma
|
2011
|
1.53
|
|
4
|
Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience.
|
Leuk Res
|
2011
|
1.49
|
|
5
|
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
|
Blood
|
2007
|
1.48
|
|
6
|
Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study.
|
Diagn Pathol
|
2007
|
1.46
|
|
7
|
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
|
Clin Cancer Res
|
2005
|
1.23
|
|
8
|
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
|
Clin Cancer Res
|
2004
|
1.16
|
|
9
|
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
|
Br J Haematol
|
2014
|
1.08
|
|
10
|
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
|
Haematologica
|
2013
|
1.06
|
|
11
|
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
|
Clin Cancer Res
|
2009
|
1.05
|
|
12
|
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
|
J Clin Oncol
|
2010
|
1.05
|
|
13
|
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
|
Leuk Res
|
2007
|
0.97
|
|
14
|
Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) acute myeloid leukemia: two case reports and a review of literature.
|
Am J Hematol
|
2004
|
0.94
|
|
15
|
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
|
Clin Cancer Res
|
2008
|
0.93
|
|
16
|
Fatal subcutaneous panniculitis-like T-cell lymphoma gamma/delta subtype (cutaneous gamma/delta T-cell lymphoma): report of a case and review of the literature.
|
Am J Dermatopathol
|
2008
|
0.88
|
|
17
|
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
|
Clin Cancer Res
|
2005
|
0.88
|
|
18
|
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
|
Ann Clin Lab Sci
|
2005
|
0.86
|
|
19
|
Diagnosis of biphenotypic acute leukemia: a paradigmatic approach.
|
Int J Clin Exp Pathol
|
2009
|
0.86
|
|
20
|
Leukopheresis for profound hyperleukocytosis.
|
Transfus Apher Sci
|
2011
|
0.83
|
|
21
|
Novel agents for the treatment of acute myeloid leukemia in the older patient.
|
J Natl Compr Canc Netw
|
2011
|
0.82
|
|
22
|
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
|
Leuk Res
|
2004
|
0.82
|
|
23
|
Unusual leukemia presentations. Case 2. Granulocytic sarcoma of the colon.
|
J Clin Oncol
|
2005
|
0.81
|
|
24
|
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
|
Am J Hematol
|
2005
|
0.81
|
|
25
|
Thoracic t(9;22)-positive granulocytic sarcoma as initial presentation of chronic myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.81
|
|
26
|
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
|
Invest New Drugs
|
2006
|
0.80
|
|
27
|
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
0.78
|
|
28
|
New treatment approaches in acute myeloid leukemia: review of recent clinical studies.
|
Rev Recent Clin Trials
|
2012
|
0.78
|
|
29
|
Cryptic chromosome abnormalities in a patient with mixed phenotype acute leukemia.
|
Leuk Lymphoma
|
2013
|
0.78
|
|
30
|
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
|
Haematologica
|
2013
|
0.77
|
|
31
|
Pearls and oy-sters: the utility of cytology and flow cytometry in the diagnosis of leptomeningeal leukemia.
|
Neurology
|
2013
|
0.76
|
|
32
|
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia.
|
Leuk Lymphoma
|
2011
|
0.76
|
|
33
|
Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
34
|
Myeloid Sarcoma of the Hepatobiliary System: A Case Series and Review of the Literature.
|
Acta Haematol
|
2016
|
0.75
|
|
35
|
Improving treatment strategies for acute lymphoblastic leukemia by combining immunotherapy and chemotherapy.
|
Leuk Res
|
2008
|
0.75
|
|
36
|
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|
|
37
|
Upfront therapy of acute myeloid leukemia.
|
Curr Oncol Rep
|
2011
|
0.75
|